My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 11 786 / https://doi.org/10.3332/ecancer.2017.786

Special Issue

Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome

Objectives: The current standard of care for patients with metastatic prostate cancer (mPCa) at diagnosis is androgen deprivation therapy (ADT) with or without anti-androgen and chemotherapy. The aim of this study was to define the role of a local radiotherapy (RT) treatment in the mPCa setting.

Methods: We retrospectively reviewed data of patients with PCa and bone oligometastases at diagnosis treated in our institution with ADT followed by cytoreductive prostate-RT with or without RT on metastases. Biochemical and clinical failure (BF, CF), overall survival (OS) and RT-toxicity were assessed.

Results: We identified 22 patients treated with ADT and external-beam RT on primary between June 2008 and March 2016. All of them but four were also treated for bone metastases. RT on primary with moderately and extremely hypofractionated regimes started after 10.3 months (3.9–51.7) from ADT. After a median follow-up of 26.4 months (10.3–55.5), 20 patients are alive. Twelve patients showed BF after a median time of 23 months (14.5–104) and CF after a median of 23.6 months (15.3–106.1) from the start of ADT. Three patients became castration resistant, starting a new therapy; median time to castration resistance was 31.03 months (range: 29.9–31.5 months). According to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC), only one patient developed acute grade 3 genitourinary toxicity. No late grade >2 adverse events were observed.

Conclusion: Prostate RT in oligometastatic patients is safe and offers long-lasting local control. When compared to ADT alone, RT on primary seems to improve biochemical control and long-term survival; however, this hypothesis should be investigated in prospective studies. Further research is warranted.

Keywords: oligometastases, prostate cancer, oligometastatic prostate cancer, radiotherapy

Loading Article Metrics ... Please wait

Related articles

Case Report: Primary non-Hodgkin lymphoma of the prostate: a case report

Abstract | Full Article | PDF Published: 12 Dec 2017 / https://doi.org/10.3332/ecancer.2017.789

Special Issue: Recent advances in radiation oncology

Abstract | Full Article | PDF Published: 30 Nov 2017 / https://doi.org/10.3332/ecancer.2017.785

Special Issue: History of the development of radiotherapy in Latin America

Abstract | Full Article | PDF Published: 30 Nov 2017 / https://doi.org/10.3332/ecancer.2017.784

Clinical Study: Prognostic value of a patient-reported functional score versus physician-reported Karnofsky Performance Status Score in brain metastases

Abstract | Full Article | PDF Published: 10 Nov 2017 / https://doi.org/10.3332/ecancer.2017.779

Review: Proton radiobiology and its clinical implications

Abstract | Full Article | PDF Published: 26 Oct 2017 / https://doi.org/10.3332/ecancer.2017.777



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence